The impact of brachytherapy on prostate cancer-specific mortality for definitive radiation therapy of high-grade prostate cancer: A population-based analysis

International Journal of Radiation Oncology Biology Physics

Volumn 83, Issue 4, 2012, Pages 1154-1159

  Shen, Xinglei ^a   Keith, Scott W ^a   Mishra, Mark V ^a   Dicker, Adam P ^a   Showalter, Timothy N ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

Brachytherapy; High risk; Prostate cancer; Radiation therapy; Seed implant

Indexed keywords

BRACHYTHERAPY; CONFIDENCE INTERVAL; EXTERNAL BEAM RADIATION THERAPY; GLEASON SCORES; HAZARD RATIO; MULTI VARIATE ANALYSIS; MULTIVARIATE MODELS; PROSTATE CANCERS; TIME FRAME;

DIAGNOSIS; ONCOLOGY; PATIENT MONITORING; PESTICIDE EFFECTS; RADIOTHERAPY; UROLOGY;

DISEASES;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BRACHYTHERAPY; CANCER GRADING; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER RISK; CANCER STAGING; EXTERNAL BEAM RADIOTHERAPY; FOLLOW UP; GLEASON SCORE; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PROSTATE CANCER; PROSTATE CANCER SPECIFIC MORTALITY; TUMOR DIFFERENTIATION; URBAN AREA;

ADENOCARCINOMA; AGE FACTORS; AGED; BRACHYTHERAPY; COMBINED MODALITY THERAPY; HUMANS; MALE; MULTIVARIATE ANALYSIS; NEOPLASM GRADING; NEOPLASM STAGING; PROSTATIC NEOPLASMS; SEER PROGRAM; UNITED STATES;

EID: 84862675606     PISSN: 03603016     EISSN: 1879355X     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2011.09.055     Document Type: Article

References (27)

1. Jemal A, Siegel R, Xu J, et al. Cancer statistics, 2010. CA Cancer J Clin 2010;60:277-300.
2. Cooperberg MR, Lubeck DP, Mehta SS, et al. Time trends in clinical risk stratification for prostate cancer: Implications for outcomes (data from CaPSURE). J Urol 2003;170.
3. D'Amico AV, Whittington R, Malkowicz BS, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. J Am Med Assoc 1998;280:969-974.
4. Bolla M, Van Tienhoven G, Warde P, et al. External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study. Lancet Oncol 2010;11:1066-1073.
5. Horwitz EM, Bae K, Hanks GE, et al. Ten-year follow-up of radiation therapy oncology group protocol 92-02: A Phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer. J Clin Oncol 2008;26:2497-2504.
6. Pilepich MV, Winter K, Lawton CA, et al. Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma - long-term results of Phase III RTOG 85-31. Int J Radiat Oncol Biol Phys 2005;61:1285-1290.
7. Lawton CA, DeSilvio M, Roach M III, et al. An update of the Phase III trial comparing whole pelvic to prostate only radiotherapy and neoadjuvant to adjuvant total androgen suppression: Updated analysis of RTOG 94-13, with emphasis on unexpected Hormone/Radiation interactions. Int J Radiat Oncol Biol Phys 2007;69:646-655.
8. Sylvester JE, Grimm PD, Wong J, et al. Fifteen-year biochemical relapse-free survival, cause-specific survival, and overall survival following I(125) prostate brachytherapy in clinically localized prostate cancer: Seattle experience. Int J Radiat Oncol Biol Phys 2011;81:376-381.
9. Fang LC, Merrick GS, Butler WM, et al. High-risk prostate cancer with Gleason score 8-10 and PSA level ≥15 ng/mL treated with permanent interstitial brachytherapy. Int J Radiat Oncol Biol Phys. In press.
10. Martinez AA, Gonzalez J, Ye H, et al. Dose escalation improves cancer-related events at 10 years for intermediate- and high-risk prostate cancer patients treated with hypofractionated high-dose-rate boost and external beam radiotherapy. Int J Radiat Oncol Biol Phys 2011;79:363-370.
11. Merrick GS, Butler WM, Galbreath RW, et al. Prostate cancer death is unlikely in high-risk patients following quality permanent interstitial brachytherapy. BJU Int 2011;107:226-232.
12. Stone NN, Potters L, Davis BJ, et al. Multicenter analysis of effect of high biologic effective dose on biochemical failure and survival outcomes in patients with Gleason score 7-10 prostate cancer treated with permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys 2009;73:341-346.
13. Rosenbaum PR, Rubin DB. The central role of the propensity score in observational studies for causal effects. Biometrika 1983;70:41-55.
14. Terakedis BE, Rossi PJ, Liauw SL, et al. A surveillance, epidemiology, and end results registry analysis of prostate cancer modality time trends by age. Am J Clin Oncol 2010;33:619-623.
15. Cooperberg MR, Broering JM, Carroll PR. Time trends and local variation in primary treatment of localized prostate cancer. J Clin Oncol 2010;28:1117-1123.
16. Deutsch I, Zelefsky MJ, Zhang Z, et al. Comparison of PSA relapse-free survival in patients treated with ultra-high-dose IMRT versus combination HDR brachytherapy andIMRT. Brachytherapy 2010;9:313-318.
17. Wong WW, Vora SA, Schild SE, et al. Radiation dose escalation for localized prostate cancer. Cancer 2009;115:5596-5606.
18. Erickson BA, Demanes DJ, Ibbott GS, et al. American Society for Radiation Oncology (ASTRO) and American College of Radiology (ACR) practice guideline for the performance of high-dose-rate brachytherapy. Int J Radiat Oncol Biol Phys 2011;79:641-649.
19. Kuban DA, Tucker SL, Dong L, et al. Long-term results of the M. D. Anderson randomized dose-escalation trial for prostate cancer. Int J Radiat Oncol Biol Phys 2008;70:67-74.
20. Bolla M, de Reijke TM, Van Tienhoven G, et al. Duration of androgen suppression in the treatment of prostate cancer. N Engl J Med 2009;360:2516-2527.
21. Picard JC, Golshayan A, Marshall DT, et al. The multi-disciplinary management of high-risk prostate cancer. Urol Oncol. In press.
22. Cahlon O, Zelefsky MJ, Shippy A, et al. Ultra-high dose (86.4 gy) IMRT for localized prostate cancer: Toxicity and biochemical outcomes. Int J Radiat Oncol Biol Phys 2008;71:330-337.
23. Peeters ST, Heemsbergen WD, Koper PC, et al. Dose-response in radiotherapy for localized prostate cancer: Results of the Dutch multicenter randomized Phase III trial comparing 68 Gy of radiotherapy with 78 Gy. J Clin Oncol 2006;24:1990-1996.
24. Valicenti R, Lu J, Pilepich M, et al. Survival advantage from higher-dose radiation therapy for clinically localized prostate cancer treated on the radiation therapy oncology group trials. J Clin Oncol 2000;18:2740-2746.
25. Zelefsky MJ, Reuter VE, Fuks Z, et al. Influence of local tumor control on distant metastases and cancer related mortality after external beam radiotherapy for prostate cancer. J Urol 2008;179:1368-1373. discussion 1373.
26. Stone NN, Stock RG, Cesaretti JA, et al. Local control following permanent prostate brachytherapy: Effect of high biologically effective dose on biopsy results and oncologic outcomes. Int J Radiat Oncol Biol Phys 2010;76:355-360.
27. Stock RG, Stone NN, Cesaretti JA, et al. Biologically effective dose values for prostate brachytherapy: Effects on PSA failure and posttreatment biopsy results. Int J Radiat Oncol Biol Phys 2006;64:527-533.